Pulmonary Disease, Chronic Obstructive Clinical Trial
Official title:
Mechanisms of COPD Exacerbation Recurrence
NCT number | NCT04024735 |
Other study ID # | 21022 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | June 1, 2019 |
Est. completion date | May 1, 2022 |
Verified date | July 2019 |
Source | University College, London |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Chronic obstructive pulmonary disease (COPD) is a common smoking-related lung disease.
Patients with COPD are at increased risk of readmission to hospitals within the following 30
days. Hospital readmissions of COPD contribute to clinical and economic burden on society.
Understanding why some COPD patients are readmitted remains a key area of unmet need.
To our knowledge, no previous study has fully investigated both the social and clinical risk
factors associated with these types of patients. The investigators want to prospectively and
comprehensively explore the possible causes, whether clinical or social factors, that cause
rehospitalisation. The investigators will be collecting demographic and clinical information
including daily physical activity level, lung function, blood and sputum samples. These
measurements will be collected at patient admission, discharge and at follow-up of 30 and 90
days. This process could lead to a better understanding of the reasons which prevent early
hospital readmission for those patients.
Status | Recruiting |
Enrollment | 166 |
Est. completion date | May 1, 2022 |
Est. primary completion date | February 1, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients who have a primary diagnosis of COPD - Patients admitted to hospital with an exacerbation. Exclusion Criteria: - Patients in whom an initial diagnosis of an AECOPD is revised to an alternative at a later phase of the study. - Patients who have a predominant history of asthma - Patients with a confirmed active malignancy - Patients who have a predominant history of bronchiectasis. - Cognitive impairment patients with a Mental Test Score (MTS) of 6 or less. - Inability to give informed consent to take part in the study |
Country | Name | City | State |
---|---|---|---|
United Kingdom | Royal Free Hospital NHS | London |
Lead Sponsor | Collaborator |
---|---|
University College, London |
United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The primary outcome is the factors that determine readmission to hospital within 30 and 90 days post discharge. | 30 and 90 days | ||
Secondary | Readmission rate at 30 days and at 3 months | 30 and 90 days | ||
Secondary | Prevalence of comorbidities between those who are and are not readmitted within 30 and 90 days. | 30 and 90 days | ||
Secondary | Changes in admission-to-discharge in within breath reactance (?Xrs5Hz) between patients who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days | ||
Secondary | Change in the modified Medical Research Council scale (mMRC) at admission, discharge and after 30 days follow-up or at readmission. | It is used to scale breathlessness, ranges from 0 to 4 which higher values represent a worse outcome. | 30 and 90 days | |
Secondary | Change in quality of life by measuring COPD assessment test (CAT) at admission, discharge and after 30 days follow-up or at readmission. | It is used to scale patient's quality of life. Range of CAT scores from 0-40 which higher scores denote a more severe impact of COPD on a patient's life. | 30 and 90 days | |
Secondary | Change in Hospital Anxiety and Depression Scale (HADS) at admission, discharge and after 30 days follow-up or at readmission. | It is used to scale patient's quality of life. The questionnaire comprises seven questions for anxiety and seven questions for depression. Each item on the questionnaire is scored from 0-3 and this means that a person can score between 0 and 21 for either anxiety or depression. The higher score indicates a worse outcome. | 30 and 90 days | |
Secondary | Prevalence of frailty between those who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days | ||
Secondary | Change in physical activity level (daily steps) following the discharge between patients who are and are not readmitted. | Step counter (pedometer) will be given to wear throughout the 30 days period to measure the daily steps. | 30 days | |
Secondary | Changes in admission-to-discharge peak inspiration flow rate (PIFR) between patients who are and are not readmitted. | The In-Check DIAL device will be used which is capable of measuring inspiratory flow rates between 0 and 120 L/min. Optimal PIFR, more than 60 L/min; and sub-optimal PIFR, 60 L/min or less). | 30 and 90 days | |
Secondary | Change in white cell count (WCC) blood biomarkers | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in C-reactive protein (CRP) blood biomarker | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in Eosinophils blood biomarker | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in Neutrophils blood biomarker | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in troponin blood biomarker | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in B-type Natriuretic Peptide (BNP) blood biomarker | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in procalcitonin blood biomarker | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in fibrinogen blood biomarker | At admission, discharge and at readmission. | 30 and 90 days | |
Secondary | Change in sputum biomarkers | This is used to assess bacteria species, load and resistance to antibiotics, and markers of inflammation such as IL-8. | 30 and 90 days | |
Secondary | Number of hospital admissions in the previous year. | The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days | |
Secondary | Number of exacerbations in the previous year. | The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days | |
Secondary | Use of long-term oxygen therapy (LTOT) | The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days | |
Secondary | Length of stay (LOS) in hospital | The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days | |
Secondary | Use of non-invasive ventilation (NIV) | The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days | |
Secondary | Previous admission to the ICU | The investigators will record it to find the difference between patients who are and are not readmitted to the hospital within 30 and 90 days. | 30 and 90 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05043428 -
The Roles of Peers and Functional Tasks in Enhancing Exercise Training for Adults With COPD
|
N/A | |
Completed |
NCT00528996 -
An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.
|
Phase 2 | |
Completed |
NCT03740373 -
A Study to Assess the Pulmonary Distribution of Budesonide, Glycopyrronium and Formoterol Fumarate
|
Phase 1 | |
Completed |
NCT05393245 -
Safety of Tiotropium + Olodaterol in Chronic Obstructive Pulmonary Disease (COPD) Patients in Taiwan: a Non-interventional Study Based on the Taiwan National Health Insurance (NHI) Data
|
||
Completed |
NCT05402020 -
Effectiveness of Tiotropium + Olodaterol Versus Inhaled Corticosteroids (ICS) + Long-acting β2-agonists (LABA) Among COPD Patients in Taiwan
|
||
Completed |
NCT04011735 -
Re-usable Respimat® Soft MistTM Inhaler Study
|
||
Enrolling by invitation |
NCT03075709 -
The Development, Implementation and Evaluation of Clinical Pathways for Chronic Obstructive Pulmonary Disease (COPD) in Saskatchewan
|
||
Completed |
NCT03764163 -
Image and Model Based Analysis of Lung Disease
|
Early Phase 1 | |
Completed |
NCT00515268 -
Endotoxin Challenge Study For Healthy Men and Women
|
Phase 1 | |
Completed |
NCT04085302 -
TARA Working Prototype Engagement Evaluation: Feasibility Study
|
N/A | |
Completed |
NCT03691324 -
Training of Inhalation Technique in Hospitalized Chronic Obstructive Pulmonary Disease (COPD) Patients - a Pilot Study
|
N/A | |
Completed |
NCT02236611 -
A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT00153075 -
Flow Rate Effect Respimat Inhaler Versus a Metered Dose Inhaler Using Berodual in Patients With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 4 | |
Completed |
NCT01009463 -
A Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT01017952 -
A Study to Evaluate Annual Rate of Exacerbations and Safety of 3 Dosage Strengths of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
|
Phase 3 | |
Completed |
NCT04882124 -
Study of Effect of CSJ117 on Symptoms, Pharmacodynamics and Safety in Patients With COPD
|
Phase 2 | |
Completed |
NCT02853123 -
Effect of Tiotropium + Olodaterol on Breathlessness in COPD Patients
|
Phase 4 | |
Completed |
NCT02619357 -
Method Validation Study to Explore the Sensitivity of SenseWear Armband Gecko for Measuring Physical Activity in Subjects With Chronic Obstructive Pulmonary Disease (COPD) & Asthma
|
Phase 1 | |
Recruiting |
NCT05858463 -
High Intensity Interval Training and Muscle Adaptations During PR
|
N/A | |
Not yet recruiting |
NCT05032898 -
Acute Exacerbation of Chronic Obstructive Pulmonary Disease Inpatient Registry Study Stage II
|